BNTC - Benitec Biopharma • Financials

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
06/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2024	-0	-22	-	21,000%	L	47	L	-51	-	-20	-0	68	-20	0	0	-	-
06/2025	0	-41	-	0%	L	97	L	-98	-	-41	-0	70	-41	0	0	-	-
06/2026	0	-51	-	0%	L	177	L	-180	-	-43	-0	99	-43	0	0	-	-

To see all financials—including updated, you must be Premium.